Preclinical and early clinical studies demonstrated that JHU-2545 can significantly reduce the uptake of radiolabeled PSMA ligands in these organs—by up to 85%—while preserving tumor targeting, thereby improving the therapeutic window of PSMA-targeted radioligand therapy. This evidence concerns the gene FOLH1 and neoplasm.